Table 2. Major bleeding rates with... | American Society of Hematology

Table 2.

Major bleeding rates with extended treatment duration of at least 1 year in clinical trials with DOACs

Study	Ref	Drug	Duration of treatment, mo	Patients, n	Events, n	%
EINSTEIN CHOICE	16	Rivaroxaban
		10 mg daily	12	1107	6	0.5*
		20 mg daily	12	1127	5	0.4*
AMPLIFY EXTENSION	17	Apixaban
		2.5 mg twice daily	12	840	2	0.2*
		5.0 mg twice daily	12	813	1	0.1*
HOKUSAI VTE	12	Edoxaban	12	1661	5	0.3†
REMEDY	13	Dabigatran	≅15	1430	13	0.9‡

Study	Ref	Drug	Duration of treatment, mo	Patients, n	Events, n	%
EINSTEIN CHOICE	16	Rivaroxaban
		10 mg daily	12	1107	6	0.5*
		20 mg daily	12	1127	5	0.4*
AMPLIFY EXTENSION	17	Apixaban
		2.5 mg twice daily	12	840	2	0.2*
		5.0 mg twice daily	12	813	1	0.1*
HOKUSAI VTE	12	Edoxaban	12	1661	5	0.3†
REMEDY	13	Dabigatran	≅15	1430	13	0.9‡

Ref, reference.

Observation started after 6 to 12 months from the index event.

Observation started at 3 months from the index event.

Observation started after ∼6 months from the index event.